Marino Stram & Associates’s GSK GSK Stock Holding History

Marino Stram & Associates’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$357K	Buy	6,475 +78	+1%	+$4.23K	0.06%	140
2025 Q4	$314K	Buy	6,397 +1	+0%	+$47	0.06%	149
2025 Q3	$276K	Buy	6,396 +188	+3%	+$7.34K	0.05%	158
2025 Q2	$238K	Buy	6,208 +39	+0.6%	+$1.49K	0.05%	161
2025 Q1	$239K	Buy	6,169 +42	+0.7%	+$1.54K	0.05%	149
2024 Q4	$207K	Buy	6,127 +30	+0.5%	+$1.08K	0.05%	164
2024 Q3	$249K	Buy	6,097 +36	+0.6%	+$1.47K	0.06%	150
2024 Q2	$233K	Buy	6,061 +1,056	+21%	+$44.4K	0.06%	150
2024 Q1	$215K	Buy	+5,005	New	+$206K	0.05%	164
2019 Q2	–	Sell	-160	Closed	-$8K	–	279
2019 Q1	$8K	Hold	160	–	–	0.01%	322
2018 Q4	$8K	Hold	160	–	–	0.01%	299
2018 Q3	$8K	Hold	160	–	–	0.01%	319
2018 Q2	$8K	Sell	160 -24	-13%	-$1.21K	0.01%	316
2018 Q1	$9K	Hold	184	–	–	0.01%	317
2017 Q4	$8K	Buy	+184	New	+$8.5K	0.01%	329

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Marino Stram & Associates's GSK Position: Q1 2026 in Review

Marino Stram & Associates increased its GSK (GSK) stake by 1.2% in Q1 2026, buying an estimated $4.23K and bringing the position to 6,475 shares worth $357K. The position accounts for 0.06% of the portfolio, ranked #140.

Marino Stram & Associates first reported a position in GSK in Q4 2017 and has held it in 15 quarters since. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Marino Stram & Associates held 6,475 shares of GSK worth $357K as of Q1 2026.
Marino Stram & Associates bought 78 GSK shares in Q1 2026, an estimated $4.23K.
GSK made up 0.06% of Marino Stram & Associates's portfolio in Q1 2026, its #140 holding.
Marino Stram & Associates first reported a position in GSK in Q4 2017 and has held it in 15 quarters since.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Marino Stram & Associates's 13F filing for Q1 2026, filed 29 Apr 2026.